Price Prediction
Moderna (MRNA) Stock Price Prediction: Analyst targets diverge as price slips back under key moving averages
Moderna (MRNA) is trading at $198.26 after a shallow 24-hour decline, with price sitting below the 7-day, 20-day and 50-day moving averages. Analyst views remain split: Morgan Stanley lifted its ta...
What happened
Moderna (MRNA) is at $198.26, down 0.10% over the last 24 hours, with a trading range of $205.39 to $190.30. That leaves the shares just under the $197.98 pivot and still below the immediate resistance at $205.67, while strong support sits at $182.89. The setup matters because price is now trading beneath the key short- and medium-term trend markers, which keeps the burden of proof on the bulls.
Analyst views are split, not unified
The clearest fundamental signal in the evidence is the widening gap between analyst targets. StockAnalysis, citing 23 analysts polled by S&P Global, shows a consensus rating of Hold and an average price target of $164.53, below the current share price. At the same time, Morgan Stanley maintained an Equal-Weight rating and raised its target to $200 from $95, while JPMorgan lifted its target to $102 from $77 and kept an Underweight rating. Piper Sandler was more constructive, raising its target to $305 and maintaining Overweight. That spread tells you the market is not working from a single earnings or valuation narrative.
Technical structure has weakened, but the stock is not broken
The trend indicators lean cautious. The 7-day SMA at $208.22 sits below the 20-day SMA at $230.69, and both are above the current price, which is consistent with a short-term distribution pattern. RSI at 39.36 is neutral but soft, while MACD is flat at -5.1053 with a zero histogram, showing weak momentum rather than a confirmed reversal. Stochastic readings are deeply washed out at 8.77 and 7.01, which can support a bounce, but only if buyers can reclaim nearby resistance.
Bollinger positioning reinforces that view. Price is near the lower band at $186.37, with %B at 0.1342, so the shares are sitting close to the lower end of the recent range rather than stretched toward the upper band. ATR of $13.01 also says the stock can move fast enough to invalidate a tight intraday setup.
Positioning is building, but flow is still mixed
On Binance perpetual futures, open interest rose 15.74% to 10,747.09 contracts, with open interest value at $2.46 million. That is constructive in the narrow sense that fresh positions are being added, but it does not tell you whether they are directional conviction or hedging. Funding is flat at 0.0000%, which is neutral. The long/short ratios lean slightly bearish: global accounts are 49.3% long versus 50.7% short, and top traders are 48.7% long versus 51.3% short. Taker flow is weaker still, with a 0.7802 buy/sell ratio, implying aggressive selling pressure in the latest 1-hour window.
What would change the tape
For a rebound to gain credibility, MRNA needs to reclaim $205.67 first and then work back above $213.07. If it fails there, the market is still treating the stock as a mean-reversion candidate inside a soft downtrend, not a clean trend breakout. On the downside, a break below $190.58 would expose $182.89 and would likely force traders to reassess whether the lower-band support is holding or failing.